These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30762889)

  • 1. Reply.
    Nguyen MH
    Hepatology; 2020 Apr; 71(4):1519. PubMed ID: 30762889
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: Hepatitis B virus infection and risk of nonalcoholic fatty liver disease: A population-based cohort study-authors' reply.
    Zhu L; Jiang J; Zhai X; Zhu F
    Liver Int; 2020 Jun; 40(6):1502-1503. PubMed ID: 32011098
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial: comorbidities in patients with chronic hepatitis B-authors' reply.
    Yoon EL; Oh H; Jun DW; Nguyen MH
    Aliment Pharmacol Ther; 2020 Sep; 52(5):893-894. PubMed ID: 32852828
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Sun et al.
    Lai JC; Wong VW; Wong GL
    Clin Infect Dis; 2020 Jun; 70(12):2748-2749. PubMed ID: 31367768
    [No Abstract]   [Full Text] [Related]  

  • 5. Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B-in Reply.
    Choi J; Ko MJ; Lim YS
    JAMA Oncol; 2019 Jun; 5(6):916-917. PubMed ID: 31021372
    [No Abstract]   [Full Text] [Related]  

  • 6. Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma.
    Su TH; Liu CJ; Tseng TC; Chou SW; Liu CH; Yang HC; Wu SJ; Chen PJ; Chen DS; Chen CL; Kao JH
    Aliment Pharmacol Ther; 2019 Mar; 49(5):589-598. PubMed ID: 30681172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term risk of acute coronary syndrome in hepatitis C virus infected patients without antiviral treatment: A cohort study from an endemic area.
    Tsai MS; Hsu YC; Yu PC; Lin CL; Kao CH
    Int J Cardiol; 2015 Feb; 181():27-9. PubMed ID: 25479534
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter: hepatitis B virus infection and risk of multiple myeloma-a meta-analysis of cohort studies. Authors' reply.
    Su TH; Chen CL; Kao JH
    Aliment Pharmacol Ther; 2020 Jan; 51(2):310-311. PubMed ID: 31880017
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparison of the level of depression and anxiety in inactive hepatitis B carriers and chronic hepatitis B patients].
    Aktuğ Demir N; Çelik M; Kölgelier S; Sümer S; Aksöz S; Demir LS; İnkaya AÇ
    Turk Psikiyatri Derg; 2013; 24(4):248-52. PubMed ID: 24310091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy.
    Hwang JP; Suarez-Almazor ME; Cantor SB; Barbo A; Lin HY; Ahmed S; Chavez-MacGregor M; Donato-Santana C; Eng C; Ferrajoli A; Fisch MJ; McLaughlin P; Simon GR; Rondon G; Shpall EJ; Lok AS
    Cancer; 2017 Sep; 123(17):3367-3376. PubMed ID: 28518219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic features and outcome after liver resection for hepatocellular carcinoma in patients with concurrent versus previous chronic hepatitis B.
    Kubo S; Tanaka H; Shuto T; Takemura S; Yamamoto T; Kanazawa A; Uenishi T; Tanaka S; Hirohashi K; Nishiguchi S; Kinoshita H
    Surg Today; 2005; 35(3):216-22. PubMed ID: 15772792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Chronic Hepatitis B Infection-Reply.
    Tang L; Kottilil S
    JAMA; 2018 Sep; 320(11):1202. PubMed ID: 30422297
    [No Abstract]   [Full Text] [Related]  

  • 13. Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study.
    Chen G; Lin W; Shen F; Iloeje UH; London WT; Evans AA
    Int J Epidemiol; 2005 Feb; 34(1):132-7. PubMed ID: 15659459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with new onset diabetes: a nationwide cohort study.
    Fu SC; Huang YW; Wang TC; Hu JT; Chen DS; Yang SS
    Aliment Pharmacol Ther; 2015 Jun; 41(11):1200-9. PubMed ID: 25846548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply to: "Validation of the TREAT-B score for hepatitis B treatment eligibility in a large Asian cohort: TREAT-B improves with age".
    Shimakawa Y; Lemoine M
    J Hepatol; 2020 Nov; 73(5):1284-1285. PubMed ID: 32859389
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to the letter by Jeng et al. 'Discrepant range of sPD-1 in different studies of Chronic hepatitis B'.
    Zhou L; Li X; Huang X; Chen L; Gu L; Huang Y
    J Viral Hepat; 2019 Jul; 26(7):931-932. PubMed ID: 31054165
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial: can hepatitis B core-related antigen be the new biomarker for hepatocellular carcinoma in nucleoside analogue-treated chronic hepatitis B? Author's reply.
    Hosaka T
    Aliment Pharmacol Ther; 2019 Apr; 49(7):955. PubMed ID: 30868631
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to: "Immunotolerant children with chronic hepatitis B - To treat or not - The dilemma continues".
    Zhu S; Zhao P
    J Hepatol; 2018 Oct; 69(4):981-982. PubMed ID: 30086997
    [No Abstract]   [Full Text] [Related]  

  • 19. Diabetes mellitus as a risk factor of liver cirrhosis in patients with chronic hepatitis B virus infection.
    Huo TI; Wu JC; Lee PC; Tsay SH; Chang FY; Lee SD
    J Clin Gastroenterol; 2000 Apr; 30(3):250-4. PubMed ID: 10777182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis.
    Değertekin H; Yalçin K; Yakut M; Yurdaydin C
    Liver Int; 2008 Apr; 28(4):494-8. PubMed ID: 18339076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.